Acuta Capital Partners LLC Has $3.20 Million Position in argenx SE (NASDAQ:ARGX)

Acuta Capital Partners LLC increased its position in shares of argenx SE (NASDAQ:ARGX) by 47.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,900 shares of the company’s stock after buying an additional 1,900 shares during the quarter. argenx accounts for 2.6% of Acuta Capital Partners LLC’s portfolio, making the stock its 16th biggest holding. Acuta Capital Partners LLC’s holdings in argenx were worth $3,198,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. J.Safra Asset Management Corp grew its holdings in shares of argenx by 590.0% during the 2nd quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock worth $30,000 after purchasing an additional 59 shares in the last quarter. Blue Trust Inc. lifted its position in argenx by 620.0% in the second quarter. Blue Trust Inc. now owns 72 shares of the company’s stock worth $28,000 after purchasing an additional 62 shares during the period. GAMMA Investing LLC boosted its stake in argenx by 51.3% during the second quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock worth $51,000 after buying an additional 40 shares in the last quarter. Cromwell Holdings LLC increased its holdings in argenx by 73.3% in the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock valued at $85,000 after buying an additional 66 shares during the period. Finally, Point72 Hong Kong Ltd acquired a new position in shares of argenx in the 2nd quarter valued at $76,000. 60.32% of the stock is currently owned by institutional investors.

argenx Price Performance

ARGX stock opened at $614.59 on Thursday. The company has a 50 day moving average price of $560.78 and a 200 day moving average price of $492.76. The stock has a market capitalization of $37.10 billion, a PE ratio of -698.40 and a beta of 0.61. argenx SE has a fifty-two week low of $327.73 and a fifty-two week high of $620.28.

argenx (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $1.29. The business had revenue of $588.88 million for the quarter, compared to analysts’ expectations of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same quarter last year, the business earned ($1.25) earnings per share. As a group, equities analysts expect that argenx SE will post 2.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft lowered shares of argenx from a “buy” rating to a “hold” rating in a research report on Friday, October 4th. William Blair upgraded argenx from a “market perform” rating to an “outperform” rating in a research note on Friday, November 1st. Baird R W cut argenx from a “strong-buy” rating to a “hold” rating in a report on Friday, November 1st. Wolfe Research raised argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price target on the stock in a research note on Tuesday, November 12th. Finally, Truist Financial increased their price objective on argenx from $540.00 to $660.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Three investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $630.42.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.